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Background
Riociguat (BAY 63-2521) is a direct NO-independent
stimulator of soluble guanylate cyclase (sGC) and is being
investigated as a new therapeutic approach for the treat-
ment of different forms of pulmonary hypertension in
clinical phase III trials. The NO-sGC-cGMP signal trans-
duction pathway is impaired in different cardiovascular
diseases, including pulmonary hypertension, heart failure
and arterial hypertension. We thus investigated the car-
dio-renal protective effects of riociguat in low-renin and
high-renin rat models of hypertension.
Materials and methods
The cardiovascular consequences of sGC stimulation were
evaluated by the long-term effects of riociguat in hyper-
tensive renin-transgenic (TG(mRRen2)27) rats treated
with the NOS inhibitor N-nitro-L-arginine methylester (L-
NAME). This high-renin study lasted 18 days and con-
tained 3 groups: control (n = 24), 3 mg/kg (n = 12) and
10 mg/kg (n = 12) riociguat orally once daily. Rats with 5/
6 nephrectomy (5/6 NX) were used as low-renin model of
hypertension. This low-renin study lasted 18 weeks and
contained 3 groups: 5/6 NX (n = 15), 5/6 NX + riociguat
(300 ppm in the solid feed; n = 12) and sham-operation
(n = 10). Blood pressure was assessed via tail-cuff repeat-
edly, at the end of the study all animals were sacrificed,
blood and organ samples were harvested for further stud-
ies.
Results
In the high-renin study part, the beneficial effects of rioci-
guat are emphasized by a significantly increased survival
in both dosages (riociguat low dose: 92%, riociguat high
dose: 100% vs 46% in L-NAME treated rennin transgenic
rats). In the low-renin study, overall survival was higher:
5/6 NX 60%, 5/6 NX + riociguat 73%, sham 100%. In
both models the blood pressure was significantly reduced
by riociguat. Moreover, in the high-renin study part rioci-
guat reduced cardiac target organ damage as indicated by
lower plasma ANP, lower relative left ventricular weight
and lower cardiac interstitial fibrosis and reduced renal
target organ damage as indicated by lower plasma creati-
nine and urea, less glomerulosclerosis and less renal inter-
stitial fibrosis. In the low-renin study part riociguat
reduced cardiac target organ damage as indicated by lower
plasma ANP, lower relative left ventricular weight, lower
myocyte diameter and lower arterial media/lumen ratio
and reduced renal target organ damage as indicated by
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improved creatinine clearance and less renal interstitial
fibrosis.
Conclusion
We demonstrate for the first time that the novel sGC stim-
ulator riociguat shows in two independent models of
hypertension a potent protection against cardiac and renal
target organ damage.